Vorasidenib is a dual IDH1/IDH2 inhibitor and showed preliminary antitumor activity in recurrent or progressive nonenhancing lower grade gliomas with good tolerance (NCT02481154).460. The gene discussed is IDH1; the disease is central nervous system cancer.